Your session is about to expire
← Back to Search
CD30 CAR T-Cells for Testicular Cancer
Study Summary
This trial is researching a new way to treat Non-Seminomatous Germ Cell Tumors (NSGCT) by combining antibodies and T cells, which may help to improve treatment options for future cancer patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I do not have active HIV, HTLV, hepatitis B, or hepatitis C infections.My cancer is a type of germ cell tumor that is not seminoma.I have had at least one treatment for my non-seminoma germ cell tumor.My cancer has returned or worsened after strong chemotherapy.
- Group 1: ATLCAR.CD30
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the recruitment process for this research still open?
"Clinicaltrials.gov reveals that recruitment for this research trial is still ongoing, with the original posting being on December 9th 2022 and subsequent updates occurring just 4 days later."
What is the current recruitment quota for this clinical trial?
"Affirmative. Clinicaltrials.gov attests that this clinical examination is presently enrolling volunteers; it was first advertised on December 9th 2022 and the listing had its last update on December 13th 2022. 18 patients are needed at a single medical centre for this trial to move forward."
What risks do individuals face when exposed to ATLCAR.CD30?
"Our evaluation unit at Power assigned ATLCAR.CD30 a safety score of 2, due to the evidence from Phase 2 trials that suggest its security; however, there is no research verifying its efficacy."
Share this study with friends
Copy Link
Messenger